SLCO1B1 and myopathy: The Swissmedic label asserts that genotyping for the presence of the SLCO1B1 c.521C allele “should be considered as part of the benefit–risk assessment in individual patients before prescribing simvastatin 80 mg, and high doses should be avoided in identified carriers of the CC genotype.” The ANVISA bula indicates that simvastatin is a substrate of “the transport protein OATP1B1” and that “co‐administration of inhibitors of OAT1B1 may lead to increased plasma concentration of simvastatin and increased risk of myopathy”, but no reference is made to PGx testing for SLCO1B1 variants.